Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 1;68(11):1379-1382.
doi: 10.1097/MAT.0000000000001659. Epub 2022 Jan 18.

SynCardia Temporary Total Artificial Heart: Single-Center Experience at a Children's Hospital

Tanya Perry  1 , David L S Morales, Chet R Villa, Alexis Benscoter, Katrina Fields, Angela Lorts
Affiliations

SynCardia Temporary Total Artificial Heart: Single-Center Experience at a Children's Hospital

Tanya Perry et al. ASAIO J. .

Abstract

The SynCardia temporary total artificial heart (TAH-t) is a pneumatically driven pulsatile device that replaces a patient's ventricles and all four valves. It is now available in two sizes and can be used in patients with sufficient chest size as a bridge to transplant or destination therapy. We describe our experience at a children's hospital with the TAH-t. Seven patients implanted with a TAH-t at Cincinnati Children's Hospital Medical Center from November 2012 to March 2021 were included. Duration of support ranged from 10 to 414 days with a median of 27 days. There was a trend toward decreased time to extubation and intensive care unit (ICU) length of stay, with the three most recent patients being extubated on postoperative day 1. Seventy-one percent of the patients were successfully transplanted following their TAH-t placement. Children and young adults with transplant graft failure requiring durable, biventricular support with a TAH-t had superior outcomes (75% survival to retransplant) than previously described.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Dr. Lorts is a consultant for Abbott, SynCardia, Medtronic, Abiomed, and Berlin Heart Inc. Dr. Morales is a consultant for Abbott, Berlin Heart, Azyio, Medtronic, and SynCardia Systems. The other authors have no conflicts of interest to report.

References

    1. Wells D, Villa CR, Simón Morales DL: The 50/50 cc total artificial heart trial: Extending the benefits of the total artificial heart to underserved populations. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 20: 16–19, 2017.
    1. Ryan TD, Jefferies JL, Zafar F, Lorts A, Morales DL: The evolving role of the total artificial heart in the management of end-stage congenital heart disease and adolescents. ASAIO J. 61: 8–14, 2015.
    1. Morales DLS, Lorts A, Rizwan R, Zafar F, Arabia FA, Villa CR: Worldwide experience with the syncardia total artificial heart in the pediatric population. ASAIO J. 63: 518–519, 2017.
    1. Villa CR, Moore RA, Morales DL, Lorts A: The total artificial heart in pediatrics: Outcomes in an evolving field. Ann Cardiothorac Surg. 9: 104–109, 2020.
    1. Spiliopoulos S, Dimitriou AM, Guersoy D, Koerfer R, Tenderich G: Expanding applicability of total artificial heart therapy: The 50-cc SynCardia total artificial heart. Ann Thorac Surg. 100: e55–e57, 2015.